<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165240</url>
  </required_header>
  <id_info>
    <org_study_id>1378-0008</org_study_id>
    <secondary_id>2017-000563-32</secondary_id>
    <nct_id>NCT03165240</nct_id>
  </id_info>
  <brief_title>This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this current trial is to investigate the safety and tolerability of&#xD;
      3 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy&#xD;
      as add-on-therapy to Angiotensin Converting Enzyme inhibitor [ACEi] or Angiotensin-receptor&#xD;
      blockers [ARB].&#xD;
&#xD;
      Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine&#xD;
      Ratio [UACR].&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Actual">May 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with drug related Adverse Events (AEs)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in morning void urine</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>BI 690517 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 690517 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 690517 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 690517</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>BI 690517 Dose 1</arm_group_label>
    <arm_group_label>BI 690517 Dose 2</arm_group_label>
    <arm_group_label>BI 690517 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial.&#xD;
&#xD;
          -  Male or postmenopausal (last menstruation ≥ 2 years ago) patients, or female patients&#xD;
             who are sterilized by either hysterectomy, bilateral salpingectomy and/or bilateral&#xD;
             oophorectomy. Male patients with partners of child-bearing potential must be willing&#xD;
             to use condoms from the time of the first intake of study drug until follow-up.&#xD;
&#xD;
          -  eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20 and &lt;&#xD;
             75 ml/min/1.73 m2 at Visit 1 measured by the central laboratory and no planned start&#xD;
             of renal replacement therapy during the trial.&#xD;
&#xD;
          -  UACR ≥ 200 and &lt;3500 mg/g in spot urine (midstream urine sample) at Visit 1 measured&#xD;
             by the central laboratory.&#xD;
&#xD;
          -  Treatment with either ACEi or ARB, stable dose since ≥ 4 weeks before Visit 1 with no&#xD;
             planned change of the therapy.&#xD;
&#xD;
          -  Patients with type 1 or type 2 diabetes mellitus, diagnosed before informed consent&#xD;
             and treated with insulin, glucagon-like peptide (GLP) 1 agonists and/or oral&#xD;
             antidiabetic medication. Treatment should have been unchanged (investigator's&#xD;
             judgment) within 4 weeks before Visit 1 and until randomisation.&#xD;
&#xD;
          -  Glycated Haemoglobin (HbA1c) &lt; 10.0% at Visit 1 measured by the central laboratory.&#xD;
&#xD;
          -  Seated SBP ≥ 110 and ≤ 180 mmHg and DBP ≥ 70 and ≤ 110 mmHg at Visit 1&#xD;
&#xD;
          -  Age at screening ≥ 18 years for male and permanently sterilized female patients and ≥&#xD;
             45 years for postmenopausal female patients.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 and &lt; 45 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with with SGLT2 inhibitors and/or inhibitors of aldosterone mediated effects&#xD;
             like mineralocorticoid receptor antagonists at visit 1 and thereafter.&#xD;
&#xD;
          -  Intake of potassium sparing diuretics like amiloride or potassium supplements during&#xD;
             the study (this period starts at Visit 1).&#xD;
&#xD;
          -  At Visit 1 cortisol peak level 30 minutes (± 5 min) after iv injection of&#xD;
             Adrenocorticotropic hormone (ACTH) is an increase by less than 200 nmol/l compared to&#xD;
             pre-ACTH injection.&#xD;
&#xD;
          -  Dual or triple blockade of the Renin Angiotensin System (RAS) (e.g. ACEi + ARB; ACEi +&#xD;
             renin inhibitor; or ARB + renin inhibitor; or ACEi + ARB + renin inhibitor) 12 weeks&#xD;
             before Visit 1 and for the duration of study.&#xD;
&#xD;
          -  History of non-diabetic renal disease according to investigator's opinion and/or renal&#xD;
             transplant recipients.&#xD;
&#xD;
          -  Hyperkalaemia (K+ &gt; 5.0 mmol/L) at visit 1 and until start of treatment measured by&#xD;
             any local or central lab.&#xD;
&#xD;
          -  Clinical signs of acute or chronic urinary tract infection 14 days before&#xD;
             randomization (based on investigator's judgement).&#xD;
&#xD;
          -  Acute febrile diseases 14 days before randomisation (based on investigator´s&#xD;
             judgement).&#xD;
&#xD;
          -  Heart failure, patients with NYHA III / IV.&#xD;
&#xD;
          -  Surgery or trauma with significant blood loss or blood donation within 12 weeks prior&#xD;
             to first administration of study medication (based on investigator´s judgement) or&#xD;
             planned surgeries during the trial e.g. hip replacement (based on investigator's&#xD;
             judgement).&#xD;
&#xD;
          -  Any other medical condition that in the investigator's opinion poses a safety risk for&#xD;
             the patient or may interfere with the study objectives.&#xD;
&#xD;
          -  Any laboratory value more than 3 times above upper limit normal (ULN) at screening&#xD;
             (visit 1) or any other laboratory value outside the reference range and clinically&#xD;
             relevant in the investigator's judgment.&#xD;
&#xD;
          -  Medical history of cancer or treatment for cancer in the last two years prior to Visit&#xD;
             1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of&#xD;
             uterine cervix, and prostatic cancer of low grade [T1 or T2] is exempted).&#xD;
&#xD;
          -  Previous enrolment in this trial.&#xD;
&#xD;
          -  Currently enrolled in another investigational device or drug study, or less than 30&#xD;
             days since ending another investigational device or drug study(s), or receiving other&#xD;
             investigational treatment(s).&#xD;
&#xD;
          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,&#xD;
             makes them an unreliable study patient or unlikely to complete the trial.&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolding Sygehus</name>
      <address>
        <city>Kolding</city>
        <zip>DK-6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg og Frederiksberg Hospital</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Nord Laënnec</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InnoDiab Forschung GmbH</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamed GmbH</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Gen. Hosp. of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatriko of Athens Group/ Iatriko of P. Faliro</name>
      <address>
        <city>P. Faliro</city>
        <zip>17562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatriko Psychikou</name>
      <address>
        <city>Psychiko</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Nélio Mendonça</name>
      <address>
        <city>Funchal</city>
        <zip>9004-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APDP - Associação Protectora dos Diabéticos de Portugal</name>
      <address>
        <city>Lisboa</city>
        <zip>1250-189</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHULN, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Beatriz Ângelo</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Res.Inst.-Compl.Iss.Cardi.Dis.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>109263</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nonstate Private Healthcare Institution &quot;Scientific Clinical Center of LLC Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baltic Med,LLC Clinic BaltMed Ozerki</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D &amp; R s.r.o.</name>
      <address>
        <city>Kosice</city>
        <zip>040 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjukhuset, Härnösand</name>
      <address>
        <city>Härnösand</city>
        <zip>871 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC Clinical Trial Consultants AB</name>
      <address>
        <city>Uppsala</city>
        <zip>75237</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset, Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>Norway</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

